Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Systemic Sclerosis Treatment Market Will Hit $500 Million by 2024

By GlobalData | December 22, 2015

The systemic sclerosis treatment market will expand from just under $316 million in 2014 to approximately $500 million by 2024, representing a modest Compound Annual Growth Rate (CAGR) of 4.7%, says research and consulting firm GlobalData.

According to the company’s latest report*, this rise, spread across the seven major markets of the US, Italy, France, the UK, Spain, Germany, and Japan, will be driven by a number of factors, including an increased use of expensive biologics, and off-label use of therapies to treat the disease.

Systemic sclerosis pathophysiology is complex and incompletely understood. Treatment varies by patient and aims to address complications, but no single therapy targets the underlying disease mechanism.

As such, Heather Leach, Ph.D., GlobalData’s Managing Analyst covering Immunology, states that while the systemic sclerosis treatment market will see some growth by 2024, unmet needs will not be completely addressed.

Leach explains: “Currently, patient needs are not being met due to a lack of anti-fibrotic drugs and disease-modifying therapies, delays in diagnosis, and a lack of safe and effective treatments.

“Ideally, rheumatologists would like one therapy that is able to address all disease manifestations, and would target, or even reverse, fibrosis. However, due to the rarity of the disease and the difficulty in treating it, there has been a lack of overall interest in the market.”

Despite this, there has been renewed interest from pharmaceutical companies, and the pipeline will see some interesting developments over the forecast period.

Leach continues: “The development of biologics for use in systemic sclerosis, specifically Roche/Genentech’s Actemra (tocilizumab) and Bristol-Myers Squibb’s Orencia (abatacept), will offer improvements over the current standard of care.

“Although these drugs will likely offer some relief for patient with fibrosis and arthritis associated with systemic sclerosis, they are unlikely to reverse fibrosis, and the evidence for their treatment of digital vasculopathy and pulmonary arterial hypertension is limited at this point.”

*OpportunityAnalyzer: Systemic Sclerosis (Scleroderma) – Opportunity Analysis and Forecast to 2024

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE